Relationship between serum IL-18 and VEGF levels in patients with prostate cancer

Nong, Shaojun; Zhang, Yueping; Zhou, Shaolin; Li, Wenguang; Ma, Limin; You, Wei

doi:10.1007/s10330-010-0702-6

Cited by 7 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Except of the elevated levels of IL-18, observed in prostate cancer, its levels were found to gradually increase with the progression of the disease [11,17,18]. One explanation for increased serum levels of IL-18 in prostate cancer patients may be the production of IL-18 by tumor cells [19], or IL-18 production induced in response to the tumor cells or other factors related to tumor development [20]. There are several single nucleotide polymorphisms in the IL-18 gene that could influence its expression or protein concentration and activity.…”

Section: Discussionmentioning

confidence: 99%

Association between interleukin-18 variants and prostate cancer in Slovak population

Jurečeková¹,

Babušíková²,

Sivoňová³

et al. 2017

neo

View full text Add to dashboard Cite

Interleukin-18 (IL-18), pro-inflammatory cytokine, plays important role in antitumor immunity. Polymorphisms in the IL-18 gene may lead to its altered production/activity and such modulate susceptibility to prostate cancer. The aim of this study was to evaluate the relationship between the -607 and +105 polymorphisms in the IL-18 gene and the risk of prostate cancer development and progression in Slovak population. The study was performed using 425 patients with prostate cancer, 270 patients with benign prostatic hyperplasia (BHP) and 263 healthy male controls. The statistically significant association of the -607 AC genotype (OR = 2.24; p < 0.001), CC genotype (OR = 1.86; p = 0.006), as well as C allele (OR = 1.27; p = 0.033) with the higher risk of prostate cancer development was observed. No association of the IL-18 -607 polymorphism and BHP was detected. The subset analysis revealed the significant association of the -607 AC genotype (OR = 2.01; p = 0.008) with development of higher-grade carcinomas (Gleason score ≥7) and the strong association of the -607 AC genotype (OR = 3.11; p < 0.001), CC genotype (OR = 2.96; p < 0.001) as well as C allele (OR = 1.51; p = 0.003) with the higher risk of prostate cancer development in the group of patients with PSA < 10 ng/ml. The -607 AC genotype was also connected with significantly higher IL-18 plasma concentrations. No association between the IL-18 +105 polymorphism and prostate cancer was observed. The analysis of the distribution of the -607 and +105 haplotypes showed significant association of the - 607 C/ + 105 A and - 607 C/ + 105 C haplotypes with the risk of prostate cancer. This study found that the IL-18 -607 promoter polymorphism could contribute to prostate cancer development in Slovak population. Its presence was also associated with development of higher-grade carcinomas and therefore may influences the prognosis and aggressiveness of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between interleukin-18 variants and prostate cancer in Slovak population

Jurečeková¹,

Babušíková²,

Sivoňová³

et al. 2017

neo

View full text Add to dashboard Cite

show abstract

“…Their findings illative the important role of IL-18 and its synergism effects on IFN-γ production in cancer patients like CRC (Nakanishi et al 2010). In another study, it was found that the serum IL-18 and vascular endothelial growth factor (VEGF) levels were significantly higher in patients with prostate cancer before operation with respect to healthy controls (p < 0.05) and these factors may be a useful prognostic marker in patients with prostate cancer (Nong et al 2010). While the findings of our study showed that IL-18 expression and serum levels in CRC patients compared with normal group increased significantly (p < 0.05) and can be used probably in diagnostic studies of cancer.…”

Section: Discussionmentioning

confidence: 95%

Comparison of interleukin 18 gene expression and its serum level between Iranian colorectal cancer (CRC) patients and healthy people

2018

View full text Add to dashboard Cite

Colorectal cancer (CRC), also known as colon cancer, rectal cancer, or colon cancer is one of the important mortal cancers of the gastrointestinal tract in Iran and worldwide. Interleukin 18 is one of the cytokines that causes inflammation and plays a real role in the inhibition of CRC development and evaluation of its rate is significant in cancer patients. The purpose of the present study was to investigate the IL-18 gene expression and its serum levels in Iranian CRC patients compared to healthy people. A total of 35 serum samples and 24 complete blood cells (CBCs) from CRC patients and as well as 20 control samples (healthy people) were collected from Al-Zahra hospital (Isfahan city, Iran) and serum and RNA specimens were isolated for molecular and serological investigations. The expression level of IL-18 gene and its serum level for comparison in both CRC patients and healthy people groups were evaluated by quantitative real-time reverse transcription PCR (q-RT-PCR) technique and ELISA assay. The comparison of IL-18 gene expression and its serum level in blood of the CRC patients and healthy people using realtime PCR and ELISA techniques were showed that this cytokine level was increased significantly in cancer patients (p < 0.05). According to the significant role of IL-18 as a pro-inflammatory cytokine in developing inflammation of gastrointestinal tract and cancer and increasing of this cytokine expression in the results of our research in CRC patients compared to the control subjects, for diagnosing or pre-screen of CRC and other cancer patients, it would be better IL-18 expression level is check in laboratories.

show abstract

Clinical value of serum interleukin-18 and nitric oxide activities in patients with prostate cancer

Nong

Zhang

et al. 2011

Chin. -Ger. J. Clin. Oncol.

Self Cite

View full text Add to dashboard Cite

Objective: The aim of the study was to estimate the clinical value of serum interleukin-18 (IL-18) and nitric oxide (NO) activities in patients with prostate cancer. Methods: The 50 patients with prostate cancer and 25 control subjects were measured in serum IL-18 by enzyme-linked immunosorbent assay (ELISA) and nitrate + nitrite level by an index of NO generation. Results: Serum IL-18 and nitrate + nitrite levels were significantly higher in patients with prostate cancer when compared to the control subjects (P < 0.05). Serum IL-18 level was significantly higher in patients with stages B, C and D when compared to patients with stage A (P < 0.05). Serum IL-18 level was significantly higher in the metastatic patients compared with the nonmetastatic patients (P < 0.01). There was no difference in serum nitrate and nitrite level between metastatic and nonmetastatic patients (P > 0.05). The serum IL-18 and nitrate and nitrite levels decreased after patients underwent surgical resection. Conclusion: Serum IL-18 level may be a useful marker to predict prognosis of patients with prostate cancer after surgery. Long-term follow-up is required to clarify this hypothesis.

show abstract

Relationship between serum IL-18 and VEGF levels in patients with prostate cancer

Cited by 7 publications

References 34 publications

Association between interleukin-18 variants and prostate cancer in Slovak population

Association between interleukin-18 variants and prostate cancer in Slovak population

Comparison of interleukin 18 gene expression and its serum level between Iranian colorectal cancer (CRC) patients and healthy people

Clinical value of serum interleukin-18 and nitric oxide activities in patients with prostate cancer

Contact Info

Product

Resources

About